Pharmacologic treatment of Alzheimer's disease: An update

American Family Physician

Volumn 68, Issue 7, 2003, Pages 1365-1372

  Delagarza, Vincent W ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; SELEGILINE; TACRINE;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; BLEEDING; BODY WEIGHT DISORDER; CHOLINERGIC NERVE CELL; COGNITION; COMA; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HUMAN; LIVER TOXICITY; MUSCLE RIGIDITY; NAUSEA; NERVE CELL LESION; NEUROFIBRILLARY TANGLE; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SENILE PLAQUE; SIDE EFFECT; STUPOR; SYNAPSE; VOMITING;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLINESTERASE INHIBITORS; DRUG MONITORING; ESTROGENS; GINKGO BILOBA; HUMANS; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; PRACTICE GUIDELINES; SELEGILINE; VITAMIN E;

EID: 0141756129     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
2. Alzheimer's Association. Caregiver stress: Signs to watch for-steps to take. Chicago: Alzheimer's Association; 1995. Accessed April 2003 at: www.alz.org/ResourceCenter/FactSheets/Brochure_%20CaregiverStress.pdf.
3. St George-Hyslop PH. Piecing together Alzheimer's. Sci Am 2000; 283:76-83.
4. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56:1683-9
5. Aricept [package insert]. Teaneck, N.J.: Eisai Inc, 2000.
6. Exelon [package insert]. East Hanover, N.J.: Novartis Pharmaceuticals Corp., 2001.
7. Reminyl [package insert]. Titusville, N.J.: Janssen Pharmaceutical Products, L.P., 2001.
8. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002;65:2263-72.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
10. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
11. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
12. Guy W, ed. ECDEU assessment manual for psychopharmacology, revised. Rockville, Md.: U.S. Department of Health and Human Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976.
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-14.
14. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86.
15. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-9.
16. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54:2269-76.
17. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67-75.
18. Farlow M, Anand R, Messina J Jr., Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41.
19. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001;5:1-137.
20. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
21. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996;47:166-77.
22. Reuters Health News. Donepezil delays nursing home placement. Accessed April 2003 at: http://www.druginfozone.org/docs/pcjw_51st_edition_in.pdf.
23. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
24. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993;328:176-83.
25. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
26. Tabet N, Birks J, Grimley Evans J, Orrel M, Spector A. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2003: CD002854.
27. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003:CD000442.
28. Physicians' desk reference. Accessed May 2003 (with password) at: www.pdr.net.
29. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
30. Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998;50:996-1002.
31. Maki PM, Resnick SM. Effects of estrogen on patterns of brain activity at rest and during cognitive activity: a review of neuroimaging studies. Neuroimage 2001;14:789-801.
32. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836-44.
33. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-15.
34. Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
35. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
36. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
37. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
38. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
39. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54:588-93.
40. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55:1409-15.
41. Miwa H, Iijima M, Tanaka S, Mizuno Y. Generalized convulsions after consuming a large amount of gingko nuts. Epilepsia 2001; 42:280-1.
42. Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001;67:33-5.
43. Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB. Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba. J Neurol Neurosurg Psychiatry 2000;68:679-80.
44. Ernst E, Pittler MH. Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 1999;17:301-8.
45. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. Am J Psychiatry 1997;154(5 suppl):1-39.
46. Fillit H, Cummings J. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II-Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council. Manag Care Interface 2000; 13:51-6.
47. Patterson C, Gauthier S, Bergman H, Cohen C, Feightner JW, Feldman H, et al. The recognition, assessment and management of dementing disorders: conclusions form the Canadian Consensus Conference on Dementia. Can J Neurol Sci. 2001;28(suppl 1):S3-16.
48. NICE issues guidance on drugs for Alzheimer's disease. National Institute for Clinical Excellence Accessed April 2003 at: www.nice.org.uk/article.asp?a=14406.
49. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
50. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease: Part II. Treatment. Am Fam Physician 2002;2525-34.
51. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44:1078-81.